N-Zyme Biomedical raised $4.6 million in a Series A to advance its Phase 2 reflux disease programs.
- Amount
- $4.6M
- Stage
- Series A
- Announced
- 22 July 2026
- Use of funds
- Phase 2 clinical programs for LPR and PPI-refractory GERD, plus regulatory, manufacturing, business development and general corporate initiatives.
- Checked
- Amount and date checked against the press source